3582 related articles for article (PubMed ID: 16490580)
1. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Herman GA; Bergman A; Liu F; Stevens C; Wang AQ; Zeng W; Chen L; Snyder K; Hilliard D; Tanen M; Tanaka W; Meehan AG; Lasseter K; Dilzer S; Blum R; Wagner JA
J Clin Pharmacol; 2006 Aug; 46(8):876-86. PubMed ID: 16855072
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
11. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
12. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
Dai H; Gustavson SM; Preston GM; Eskra JD; Calle R; Hirshberg B
Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
[TBL] [Abstract][Full Text] [Related]
15. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
17. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
18. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Mistry GC; Luo WL; Liu Q; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman GA; Wagner JA; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):307-13. PubMed ID: 17571284
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
20. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.
Katz LB; Gambale JJ; Rothenberg PL; Vanapalli SR; Vaccaro N; Xi L; Sarich TC; Stein PP
Diabetes Obes Metab; 2012 Aug; 14(8):709-16. PubMed ID: 22340428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
